Literature DB >> 32639558

Development of an Electronic Definition for De-escalation of Antibiotics in Hospitalized Patients.

Rebekah W Moehring1, Elizabeth S Dodds Ashley1, Angelina E Davis1, April Pridgen Dyer1, Alice Parish2, Xinru Ren2, Yuliya Lokhnygina2, Lauri A Hicks3, Arjun Srinivasan3, Deverick J Anderson1.   

Abstract

BACKGROUND: Antimicrobial stewardship programs (ASPs) promote the principle of de-escalation: moving from broad- to narrow-spectrum agents and stopping antibiotics when no longer indicated. A standard, objective definition of de-escalation applied to electronic data could be useful for ASP assessments.
METHODS: We derived an electronic definition of antibiotic de-escalation and performed a retrospective study among 5 hospitals. Antibiotics were ranked into 4 categories: narrow-spectrum, broad-spectrum, extended-spectrum, and agents targeted for protection. Eligible adult patients were cared for on inpatient units, had antibiotic therapy for at least 2 days, and were hospitalized for at least 3 days after starting antibiotics. Number of antibiotics and rank were assessed at 2 time points: day of antibiotic initiation and either day of discharge or day 5. De-escalation was defined as reduction in either the number of antibiotics or rank. Escalation was an increase in either number or rank. Unchanged was either no change or discordant directions of change. We summarized outcomes among hospitals, units, and diagnoses.
RESULTS: Among 39 226 eligible admissions, de-escalation occurred in 14 138 (36%), escalation in 5129 (13%), and antibiotics were unchanged in 19 959 (51%). De-escalation varied among hospitals (median, 37%; range, 31-39%, P < .001). Diagnoses with lower de-escalation rates included intra-abdominal (23%) and skin and soft tissue (28%) infections. Critical care had higher rates of both de-escalation and escalation compared with wards.
CONCLUSIONS: Our electronic de-escalation metric demonstrated variation among hospitals, units, and diagnoses. This metric may be useful for assessing stewardship opportunities and impact.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antibiotic; antimicrobial stewardship; de-escalation; metric; outcome

Mesh:

Substances:

Year:  2021        PMID: 32639558     DOI: 10.1093/cid/ciaa932

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

1.  Real-world Antimicrobial Stewardship Experience in a Large Academic Medical Center: Using Statistical and Machine Learning Approaches to Identify Intervention "Hotspots" in an Antibiotic Audit and Feedback Program.

Authors:  Katherine E Goodman; Emily L Heil; Kimberly C Claeys; Mary Banoub; Jacqueline T Bork
Journal:  Open Forum Infect Dis       Date:  2022-06-10       Impact factor: 4.423

2.  Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT) Reveals Improvements in the Treatment of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae in Patients from the Veterans Health Administration.

Authors:  Federico Perez; Roberto Viau Colindres; Brigid M Wilson; Elie Saade; Robin L P Jump; Ritu Banerjee; Robin Patel; Scott R Evans; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

3.  Use of Contact Networks to Estimate Potential Pathogen Risk Exposure in Hospitals.

Authors:  Kaniz Fatema Madhobi; Ananth Kalyanaraman; Deverick J Anderson; Elizabeth Dodds Ashley; Rebekah W Moehring; Eric T Lofgren
Journal:  JAMA Netw Open       Date:  2022-08-01

4.  Epidemiology, clinical relevance and prognosis of staphylococci in hospital-acquired postoperative intra-abdominal infections: an observational study in intensive care unit.

Authors:  Kévin Boussion; Nathalie Zappella; Nathalie Grall; Lara Ribeiro-Parenti; Grégory Papin; Philippe Montravers
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.